Today: The Guggenheim Reiterates Buy Rating for Teva Pharmaceutical Industries Ltd. (TEVA)

The Guggenheim Reiterates Buy Rating for Teva Pharmaceutical Industries Ltd. (TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by investment analysts at Guggenheim in a note issued to investors on Wednesday. They currently have a $80.00 price objective on the stock. Guggenheim’s price target would suggest a potential upside of 77.54% from the stock’s previous close.

Several other equities research analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research report on Wednesday, June 15th. Mizuho reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Sunday, July 17th. RBC Capital Markets set a $71.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Sunday, September 11th. Bank of America Corp. set a $72.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Saturday, October 1st. Finally, Piper Jaffray Cos. restated a “neutral” rating and issued a $57.00 price target (up previously from $55.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, August 8th. Seven research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $66.98.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded down 0.75% during midday trading on Wednesday, hitting $45.06. 4,526,179 shares of the stock traded hands. Teva Pharmaceutical Industries has a 52 week low of $44.60 and a 52 week high of $66.55. The stock has a market capitalization of $41.18 billion, a P/E ratio of 30.10 and a beta of 0.74. The firm has a 50-day moving average price of $50.06 and a 200-day moving average price of $52.52.

10/08/guggenheim-reiterates-buy-rating-for-teva-pharmaceutical-industries-ltd-teva.html

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.05. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The company had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.86 billion. During the same period last year, the company posted $1.43 EPS. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. On average, equities analysts predict that Teva Pharmaceutical Industries will post $5.24 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Monday, August 22nd were issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend was Thursday, August 18th. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently 77.85%.

A number of large investors have recently added to or reduced their stakes in TEVA. Sharkey Howes & Javer boosted its stake in shares of Teva Pharmaceutical Industries by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock valued at $101,000 after buying an additional 358 shares in the last quarter. Hudock Capital Group LLC boosted its stake in shares of Teva Pharmaceutical Industries by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock valued at $103,000 after buying an additional 564 shares in the last quarter. Washington Trust Bank boosted its stake in shares of Teva Pharmaceutical Industries by 2.7% in the third quarter. Washington Trust Bank now owns 2,232 shares of the company’s stock valued at $103,000 after buying an additional 58 shares in the last quarter. WFG Advisors LP boosted its stake in shares of Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock valued at $104,000 after buying an additional 256 shares in the last quarter. Finally, Flow Traders U.S. LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at $105,000. 63.35% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Related posts

Leave a Comment